It started as a respiratory illness – or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that ...

Findings indicate a sharp drop in immunity after Omicron infection, stressing the necessity for updated vaccines to enhance ...

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID ...

In a breakthrough for influenza research, scientists have discovered immune cells that can recognize influenza (flu) viruses ...

SARS-CoV-2 infection was associated with more rapid coronary plaque progression and significantly increased risk for adverse ...

The study explores the potential of chitosan derivatives as novel inhibitors against the wild-type and emerging variants of ...

The virus that causes COVID-19 also increases the risk of a heart attack or stroke, warns new research. SARS-CoV-2 is linked ...

A new study found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was associated with the rapid growth ...

Researchers have developed a powerful tool that can detect variants of SARS-CoV-2 with high transmission potential before ...

Infection with the SARS-CoV-2 Omicron variant confers weak, short-term protection against reinfection, compared with the much ...

Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...

In total, 5% of dogs and 13% of cats tested positive for COVID-19 on polymerase chain reaction, and 25% and 36%, respectively ...